Can Following The Insiders Into VMware, Inc. (VMW) and NewLink Genetics Corp (NLNK) Lead To Big Rewards?

One strategy that has proven to be effective over time in determining whether a stock is moving higher is insider accumulation, due to one simple reason. Insiders sell shares for a variety of reason, but they buy them, just like us, because they believe the stock will move higher. Furthermore, they have an enviable vantage point of their company’s day-to-day operations, and they may also have a large investment of their own, which they would like to see increase in value. The following stocks have notable insider purchases, which may provide you with a nice stating point for your own investment research.

VMware-Nicira ImpactA cloudy contender

Virtualization and infrastructure solutions giant VMware, Inc. (NYSE:VMW) has seen better days; it recently got slammed on a disappointing earnings report. The outlook was not pretty, and the stock now sits virtually at its $76.25 52-week low.

Nonetheless, major shareholder and storage giant EMC Corporation (NYSE:EMC) seems to think the stock will move higher in the foreseeable future. From Jan. 31 to Feb. 2, EMC collectively gobbled up 289,500 shares at an average price of $77.70. That equates to an impressive $22.5 million worth of stock, and brings its total ownership to over 41.5 million shares now, or approximately 10% of the total VMware shares outstanding.

This is obviously a strong vote of confidence. EMC apparently thinks that VMware’s stock will move higher, and that the big hit in the share price does make the company more attractive. However, VMware is still trading at some lofty valuations for this Fool, with a trailing price-to-earnings ratio of 45, a price-to-sales of more than 7, and an enterprise value-to-EBITDA ratio of 24.

So while I still believe the cloud computing space has much more growth ahead of it as more of the public realizes its potential, I just cannot get behind a company that is still a little too expensive for my taste at this time.

If I were looking to place a bet on VMW, I think going indirectly through its major shareholder, EMC, makes more sense to me. EMC’s stock there trades at a much more reasonable (albeit not growing as fast as VMW) trailing P/E of 20, just over 2.5 times its price to sales, and 8.5 times its enterprise value to EBITDA.

Moreover, they both have basically the same returns on assets and equity of 6% and 14% respectively, so I think buying EMC is in some ways buying VMW on sale. Moreover, you get EMC’s highly profitable and consistently growing data storage business. With the continued growth of internet and other data uses, investors can reasonably expect that growth will continue and the stock will move higher over time.

A biotech bonanza?

NewLink Genetics Corp (NYSE:NLNK) is a biopharmaceutical company focused mainly on cancer treatment options and solutions. The company has been range-bound the last year, and it’s currently stuck in the middle of its 52-week range.

Nonetheless, major shareholder Stine Seed Farm sees rosier days ahead, buying a massive 880,000 shares on Feb. 4 at $11.40 apiece, equating to just over $10 million worth of stock. That brings Stine Seed’s total ownership to more than 7 million shares, or approximately 35% of the total shares outstanding. This is a very strong vote of confidence, because Stine Seed’s latest purchase equates to approximately 4% of the total value of the company.

Looking more closely at NewLink, we can see some positive developments. The company has either met or exceeded consensus analyst estimates in each of the last three quarters. It’s also cleaned up its balance sheet, now holding virtually no debt and approximately $27 million in net cash.

As is the case with most speculative biotechnology companies, NewLink’s returns on equity and assets are atrocious. The company usually has no earnings to speak of until its hopefully get approval for the next blockbuster drug. Of course, whether it actually will is anybody’s guess. If it does strike gold, investors will be handsomely rewarded — but if the trials do not go as well as expected, buyer beware.

As a more conservative investor, I would look more towards a well-established biotech firm like Amgen, Inc. (NASDAQ:AMGN). The company has a consistent revenue stream, now exceeding $17 billion annually; great returns on equity of 23%; and it’s trading at virtually its expected growth rate. At a current paltry 26% payout ratio, investors can expect its consistently growing 2.2% dividend yield to continue being hiked in the near future.

Moreover, as big pharmaceutical companies such as Pfizer and Merck continue to look for any way to replenish their depleting pipeline, well-received Amgen drugs such as Neulasta and Neupogen are thriving. They could make Amgen a possible buyout candidate, since Pfizer and Merck could support such a large acquisition. Of course, I never base my investment decision on an expected buyout — but it could still become a nice surprise.

Follow the inside scoop

Overall, I think that with such large insider buying that we see here, any shrewd investor should take notice and put these stocks on their radar.

The article Can Following The Insiders Into These Stocks Lead To Big Rewards? originally appeared on Fool.com and is written by Brian Gorban.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!